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Abstract:  Purpose: To compile the safety aspects of the corneal collagen cross-linking (CXL) by means of the 
riboflavin/UVA (370 nm) approach. 
Materials and Methodology: Analysis of the current treatment protocol with respect to safety during CXL. 
Results: The currently used UVA dose density of 5.4 J/cm
2 and the corresponding irradiance of 3 mW/cm
2 are below the 
known damage thresholds of UVA for the corneal endothelium, lens, and retina. Regarding the photochemical damages 
due to the free radicals the damage threshold for endothelial cells is 0.35 mW/cm
2. In a 400μm thick corneal stroma 
saturated with riboflavin, the irradiance at the endothelial level is about 0.18 mW/cm
2, which is a factor of 2 smaller than 
the damage threshold. 
Conclusion: As long as the corneal stroma treated has a minimal thickness of 400 microns (as recommended), neither 
corneal endothelium nor deeper structures such as lens and retina will suffer any damages. The light source should 
provide a homogenous irradiance avoiding hot spots. 
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INTRODUCTION 
  From the beginning of the CXL research the safety of the 
treatment stood in the center of attention because this 
procedure was not applied in tissue engineering of isolated 
collagen structures. The aim was to develop a clinically 
applicable method for eyes in vivo to create additional 
chemical bonds inside the corneal stroma by means of a 
highly localized photopolymerization while minimizing 
exposure to the surrounding structures of the eye [1,2]. There 
were some points to taken under consideration: 
-  The duration of the treatment should not be too long. 
-  The transparency of the cornea should not be 
changed. 
-  The cross-linking effect should only include the 
cornea. 
(Cross linking and damaging of adjacent tissue should be 
avoided). 
  It was a challenge in the optimizing of the treatment 
parameters to reach a sufficient biomechanical effect in the 
cornea and avoid damage of the endothelium, lens or retina. 
The treatment parameters should fullfil two requirements: 
the biomechanical effect and the safety. Many investigations 
were necessary for the fine-tuning of these treatment 
parameters [3-8]. 
1. The Choosing of the Photochemical Cross-Linking 
  There are two different collagen cross-linking methods: 
the chemical cross-linking uses solutions like glutaraldehyde,  
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transglutaminase, genepin and nitroalcohol, and the 
photooxidative (also called physical) cross-linking uses light 
especially UV-light [2]. The application of liquid cross-
linker to the curved cornea is not easy and the diffusion of 
the liquid cannot be controlled during application. Thus, we 
decided to use the photooxitative cross-linking for a safer 
application [3, 9]. 
2. The Choosing of the Treatment Parameters with 
Respect to Safety 
  Singlet oxygen is necessary for the photooxidative cross-
linking. Riboflavin is one of the most potent producers of 
these oxygen radicals. Riboflavin (vitamin B2) is not toxic 
and it is also used as a food dye. However, riboflavin is not 
only a photosensitizer - it acts also as a UV absorber. Since 
the UV light is effective only in the absorbed areas, it is 
desirable that the irradiation is absorbed in about 400 m 
thick corneal stroma tissue [10, 11]. 
  This high absorption is achieved by the selection of the 
wavelength of the used UV light at 370 nm, a wavelength 
that corresponds to one of the riboflavin’s absorption 
maxima. For the absorption of ultraviolet light in the cornea 
the concentration of the superficially applied riboflavin 
solution of 0.1% and the time course of the diffusion process 
is relevant. Applied riboflavin must diffuse into the corneal 
stroma and this process requires certain time [11]. The intact 
epithelium acts as a barrier that inhibits the diffusion of 
riboflavin (molecular weight 376.37 g/mol) into the cornea 
[3, 12, 13]. For that reason the epithelium must be debrided 
from the intended treatment area because this simple 
procedure removes a diffusion barrier for the riboflavin 
molecule and speeds saturation of the corneal stromal tissue 
[3]. Then riboflavin diffuses through the cornea and a 
concentration gradient is formed. Though the highest 
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[14], however after 20-30 min a sufficient concentration is 
reached also in the posterior stroma [11]. As a result only a 
small part of the UV penetrates through the cornea and thus 
deeper ocular structures like lens or retina are protected from 
the potential hazards of free radical formation. After the 
riboflavin has traversed the cornea, it enters into the anterior 
chamber. The aqueous humour without riboflavin does not 
have any relevant absorption at 370 nm but clinically it starts 
to stain after about 5 min of surface exposure to riboflavin. 
By means of slit lamp inspection using blue light the surgeon 
has to assure that riboflavin has appeared in the anterior 
chamber before the UV-irradiation has started [15]. The 
yellow staining of the anterior chamber serves as a safety 
feature, indicating that the riboflavin has penetrated the 
cornea and the cornea is thoroughly saturated. Only a 
circular area of 8 mm in diameter is then exposed to UV-
light with a wavelength of 370 ± 5 nm and an irradiance of 3 
mW/cm for a total time of 30 min. This corresponds to a 
total dose of 3.4 J (J =Joule) or a total dose density of 5.4 
J/cm
2 to the cornea. Lambert-Beer`s law yields a reduction 
of the irradiance due to absorption in a 400 μm-thick stroma 
satured with riboflavin (Fig. 1). Therefore, due to the 
additional riboflavin shielding all structures behind the 
corneal stroma including the cornea endothelium, anterior 
chamber, iris, lens, and retina are theoretically exposed to a 
residual UV-dose density that is less than 1 J/cm
2 as 
recommended by the UV-guidelines [11, 16]. 
  The aim in the biomechnical effect is to reach a stiffness 
of the keratoconic cornea similar to the normal one. The 
stiffness of the keratoconic cornea is about 70% of a healthy 
cornea [17]. It was not our aim to harden the cornea extremly 
and to convert it in a non-physiological range. For that 
reason we choose a low irradiance of 3 mW/cm for 30 
minutes. Thus, we increase the stability of the cornea and the 
cross-linked collagen network allowing keratocyte 
repopulation [18, 19]. The strong cross-linked collagen 
inhibits the repopulation of cells [20]. 
3. Design of a Light Source with Respect to Safety 
  All the above safety considerations are based on an 
irradiance that is homogenous within the field of UVA-
application. However, if optical inhomogenities such as hot 
spots are present the damage thresholds may be exceeded 
locally leading to localized endothelial damage although the 
average irradiance may be less than 3mW/cm
2. Therefore, 
clinically used light sources must guarantee a perfect 
homogenity of the irradiance across the beamed area. 
  The UV illumination system was designed based on 
ultraviolet LEDs with a peak emmitance at 365 nm. A beam 
path according to Koehler
 [21] is focused through a variable 
diaphragm onto the corneal surface with a special beam 
homogenizing micro structure
  [22] in order to ensure 
homogenity of illumination on the cornea. In the optical 
design according to Koehler the UV light diaphragm is 
imaged onto the corneal front surface and as a consequence 
is the UV light that is focused on the front surface of the 
cornea strongly scattered in the ocular media behind the 
cornea. Thus the safety considerations are fully applied and 
the real radiant exposures in the eye are probably even lower. 
In order to obtain an estimate of the real intraocular 
illumination intensities during treatments using the presented 
homogenizing UV light source, the radiant exposure was 
experimentally measured in the retinal plane of porcines eyes 
[23]. 
4. Prevention of the Corneal Endothelium Damage 
  The photopolymerization process inducing additional 
cross-links in the corneal stroma is carried out by free 
radicals mediated by the riboflavin irradiated with UV-light. 
Such radicals can create cell damages that may be tolerable 
in keratocytes population but not in the corneal endothelium. 
The cytotoxicity of the riboflavin/UVA treatment on 
keratocytes and endothelium cells was studied by Wollensak 
and coworkers and the cytotoxic threshold of the 
UVA/Riboflavin for endothelial cells and keratocytes was 
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determined [4-7]. The cell population that is the most critical 
to suffer from damages either from UV-light directly or from 
the free radicals is the corneal endothelium because it is 
immediately adjacent to the corneal stroma and these cells in 
the normal human cornea have low regenerative capacity. 
With the above mentioned treatment parameters the 
cytotoxic threshold of the endothelial cells is not reached. 
Clinical studies provide the best evidence. By means of 
confocal microscopy in keratoconus eyes treated with CXL 
no pathologic signs of the endothelial damage were detected 
[24, 25]. In other clinical studies using the recommended 
treatment parameters there was no change in the endothelial 
cell count observed after CXL [9, 26, 27]. 
CONCLUSION 
  In summary, regarding the safety issues, procedure 
should respect the following criteria: (1) to facilitate 
diffusion of riboflavin the epithelium should be removed; (2) 
a 0.1% riboflavin solution must be applied for 30 minutes 
before UV–exposure, during this treatment riboflavin does 
not only serve as photosensitizer but also as a UV-blocker; 
(3) the UV-irradiance of 3 mW/cm must be homogenous 
and must have a wavelength of 370 nm; and (4) the minimal 
thickness of corneal stroma to be cross-linked must at least 
400 micrometer. Fulfilling these criteria a damage of the 
endothelium, the lens or the retina should not be expected. 
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